Determining PGRN serum levels in Belgian frontotemporal lobar degeneration patients.

Recently we demonstrated that mutations in PGRN explain a significant fraction of the genetic etiology of frontotemporal lobar degeneration (FTLD) and a follow-up study identified serum PGRN as a potential biomarker for FTLD with underlying PGRN pathology. In the frame of this project we wish to confirm and expand these initial findings by measuring serum PGRN levels trough ELISA in a large sample of Belgian FTLD patients.

Keywords:FRONTOTEMPORAL DEMENTIA, PROGRANULIN, SERUM, ELISA

Disciplines:Genetics, Systems biology, Molecular and cell biology